Physician profile
Alan Kurfirst
NPI 1245338243
$2,046.27
in general payments reported to CMS, 2019-2025
12 companies · $83.00 in 2025
The $83.00 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $133 · 2021: $184 · 2022: $295 · 2023: $194 · 2024: $129 · 2025: $83.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $769.00 | 2019-2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $654.51 | 2019-2021 | |
| Heru, INC. | $224.67 | 2022 | |
| Bausch & Lomb Americas INC. | $93.47 | 2023-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $89.34 | 2019-2024 | Precision 1 |
| Sun Pharmaceutical Industries INC. | $57.49 | 2022-2025 | Cequa |
| Visioneering Technologies, INC. | $47.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.55 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $18.61 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $17.68 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kurfirst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.